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Abstract
Background: Clinical guidelines are intended to improve healthcare. However, even if guidelines are excellent,
their implementation is not assured. In subfertility care, the European Society of Human Reproduction and
Embryology (ESHRE) guidelines have been inventoried, and their methodological quality has been assessed. To
improve the impact of the ESHRE guidelines and to improve European subfertility care, it is important to optimise
the implementability of guidelines. We therefore investigated the implementation barriers of the ESHRE guideline
with the best methodological quality and evaluated the used instrument for usability and feasibility.
Methods: We reviewed the ESHRE guideline for the diagnosis and treatment of endometriosis to assess its
implementability. We used an electronic version of the guideline implementability appraisal (eGLIA) instrument.
This eGLIA tool consists of 31 questions grouped into 10 dimensions. Seven items address the guideline as a
whole, and 24 items assess the individual recommendations in the guideline. The eGLIA instrument identifies
factors that influence the implementability of the guideline recommendations. These factors can be divided into
facilitators that promote implementation and barriers that oppose implementation. A panel of 10 experts from
three European countries appraised all 36 recommendations of the guideline. They discussed discrepancies in a
teleconference and completed a questionnaire to evaluate the ease of use and overall utility of the eGLIA
instrument.
Results: Two of the 36 guideline recommendations were straightforward to implement. Five recommendations
were considered simply statements because they contained no actions. The remaining 29 recommendations were
implementable with some adjustments. We found facilitators of the guideline implementability in the quality of
decidability, presentation and formatting, apparent validity, and novelty or innovation of the recommendations.
Vaguely defined actions, lack of facilities, immeasurable outcomes, and inflexibility within the recommendations
formed barriers to implementation. The eGLIA instrument was generally useful and easy to use. However,
assessment with the eGLIA instrument is very time-consuming.
Conclusions: The ESHRE guideline for the diagnosis and treatment of endometriosis could be improved to
facilitate its implementation in daily practice. The eGLIA instrument is a helpful tool for identifying obstacles to
implementation of a guideline. However, we recommend a concise version of this instrument.
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Clinical guidelines are important tools for improving the
quality, effectiveness, and appropriateness of healthcare
[1-5]. They are intended to bridge the gap between
research and practice and to assist clinicians and
patients in clinical decision making [2,6,7]. Moreover,
they can reduce the use of unnecessary diagnostic tests
and treatments [8]. However, adherence to guidelines is
often poor and not self-evident [9-13]. Implementation
of guidelines requires ‘turning changes in attitude and
knowledge into changes in medical practice’ [14]. To
improve guideline adherence and consequently health-
care, the implementability of the guidelines should be
taken into account [15,16].
Factors that influence the implementability of guide-
lines can be divided into facilitators that promote imple-
mentation and barriers that oppose implementation
[17]. Various studies describe these factors [17-20],
which can be classified as factors relating to physicians
or patients, to the methodological quality of a guideline
(including the clarity and applicability of its recommen-
dations), and to the external context (e.g., legislation and
required facilities) [21].
Implementation of guidelines is significant in many
medical disciplines and is especially important in subfer-
tility care because it is concerned with social, financial,
legal, and ethical implications [22]. Subfertility is defined
as lack of conception after at least one year of unpro-
tected intercourse [23]. Approximately 80 million people
worldwide suffer from this disorder [24]. More than half
of subfertile couples seek medical care [25]. Clinical
guidelines can be helpful to set standards and to orga-
nise the care properly. Emslie and coworkers showed
improvements in the process of subfertility care with
the use of guidelines [1]. Collaboration in developing
the European subfertility guidelines could improve their
scientific validity and promote international consensus
on their clinical content [4,26,27]. This may help reduce
practice variation and quality defects at an international
level.
The European Society for Human Reproduction and
Embryology (ESHRE) is one of the international organi-
sations that participates in the process of developing
international clinical practice guidelines in the area of
reproductive medicine [28]. Nelen and coworkers evalu-
ated 11 ESHRE guidelines with the validated Appraisal
of Guidelines for Research and Evaluation (AGREE)
instrument [29,30]. The methodological quality of most
of these clinical ESHRE guidelines was poor, while the
quality of five of the guidelines was better. The ESHRE
guideline for the diagnosis and treatment of endome-
triosis had the highest methodological quality. However,
data about the implementability of these guidelines are
not available. Such data are crucial for better application
of the ESHRE guidelines.
Various methods have been developed for assessing
guideline implementability [31,32]. Shiffman and cowor-
kers recently developed an instrument, the guideline
implementability appraisal (GLIA) instrument, for which
evidence of content validity and support for construct
validity were obtained [33]. The instrument contains a
series of validated questions for assessing the relative
ease of implementation of guideline recommendations.
It identifies potential obstacles to implementation that
are primarily intrinsic to the guideline. This makes the
instrument useful for guideline developers to remedy
defects in guidelines and for guideline implementers to
identify barriers [33]. Moreover, an electronic version of
this tool has been developed: the eGLIA instrument.
We investigated the implementability of the ESHRE
guideline on endometriosis with the eGLIA instrument
to identify potential barriers to implementation and to
refine the guideline. We also evaluated the eGLIA
instrument for its usefulness and feasibility as an apprai-
sal tool for improving the implementability of a
guideline.
Methods
Clinical practice guideline
We reviewed the ESHRE guideline for the diagnosis and
treatment of endometriosis, which contains 36 recom-
mendations (Additional File 1, Appendix 1). We used
the published paper version of the guideline for our
appraisal [34].
Appraisal instrument
The GLIA instrument, developed by Shiffman and cow-
orkers, was used to identify obstacles to implementation
[33] (Additional file 2, Appendix 2). The first part of the
GLIA instrument consists of seven global dimension
questions (Q1-Q7) that relate to the guideline as a
whole. The second part of the instrument consists of 24
questions for assessing the implementability of each
individual recommendation (Q8-Q31). These questions
are grouped into nine dimensions: decidability (n =3 ) ,
executability (n = 2), effect on process of care (n =2 ) ,
presentation and formatting (n = 2), measurable out-
comes (n = 2), apparent validity (n = 2), novelty (n =3 ) ,
flexibility (n = 4), and computability (n =4 ) .T h el a s t
four questions rating computability are optional and
o n l ya p p l yw h e na ne l e c t r o n i ci m p l e m e n t a t i o ni s
planned. All items have four response categories: ‘Y’
(yes), ‘N’ (no), ‘NA’ (not applicable), and ‘?’ (unsure).
The GLIA instrument provides additional space for
comments about how a recommendation fulfils or fails
to fulfil a criterion. Additional File 3, Appendix 3 gives
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provide an overall judgement of the implementability of
the guideline as a whole. Therefore, we added an extra
question to seek the general opinion of the appraisers
about the implementability of the guideline. We used a
five-point Likert scale (1 = definitely not implementable,
5 = definitely implementable) to assess the rating.
We used eGLIA, the electronic version of the GLIA
instrument http://nutmeg.med.yale.edu/eglia/. This elec-
tronic tool has an advantage over the paper version
because it is useful and feasible to use with limited
training and time [35]. Moreover, the electronic version
offers automatic data storage, which was especially
advantageous for our appraisers coming from different
countries.
Composition of the panel of appraisers
We composed a balanced panel of 10 clinical and meth-
odology experts. We selected six clinical experts: two
developers of the guideline about endometriosis (TD
and GD), one expert on endometriosis (AS), and three
experts in subfertility care from the Special Interest
Group on Safety and Quality in Assisted Reproductive
T e c h n o l o g y( S I GS Q U A R T )f r o mE S H R E( C B ,K N ,a n d
PS). Furthermore, two researchers from the department
of Obstetrics and Gynaecology (LD and WN) and two
experts in quality of care (JB and CM), one of whom
had special expertise with the eGLIA instrument (CM),
participated in this study. The appraisers came from
Belgium, Sweden, the Netherlands, and New Zealand.
Appraisal of the guideline
We asked the panel members to read the ESHRE guide-
line for the diagnosis and treatment of endometriosis
and to assess it with the eGLIA instrument using their
own computers.
We collected the individual scores of the participants
and determined the discrepancies in scoring. We sent
every appraiser an overview of his or her answers and
the frequencies in the other participants’ scores. This
overview made differences in scoring clear for each
assessor. There was a one-hour telephone conference to
discuss the discrepancies between assessments and to
come to a final score, as the eGLIA tool indicates to do.
The content experts helped resolve questions answered
with ‘?’ (unsure) in this phone conference. Then the par-
ticipants decided conclusively whether a recommenda-
tion had met a particular criterion or failed it. Each final
decision was based on agreement reached by an absolute
majority of the participants (difference ≥2).
Analysis
Items voted for by an absolute majority of participants
were marked. Items with the answer ‘No’ were seen as
barriers. Items with the answer ‘Yes’ were seen as facili-
tators. Items with a slight majority (one-point differ-
ence) were treated as borderline barriers. Questions that
were answered ‘No’ and did not satisfy the criterion
were listed as barriers, and recommendations for adjust-
ments or changes were made.
Process evaluation of eGLIA
The appraisers individually completed a questionnaire
(12 questions) about their experience with the eGLIA
instrument immediately after they used it. The question-
naire included items about time investment, clarity and
usability of the instrument, and relevance of the eGLIA
tool questions. The questions were evaluated on a five-
point Likert scale ranging from 1 (strongly disagree) to
5 (strongly agree). We performed descriptive statistical
analyses with SPSS for Windows Release 14.0 Standard
Version (SPSS Inc., Chicago, IL, USA).
Results
Appraisal of the guideline
Eight of the 10 participants appraised all 36 recommen-
dations with 24 questions. One appraiser assessed 25
recommendations, and one participant appraised only 7
recommendations because of lack of time.
In the final report (Additional File 4, Appendix 4), 69
questions are marked as barriers (in red) and 501 as
facilitators (in green). Twelve borderline barriers (doubt-
ful items with only one-point difference) were marked
separately (in orange) with inside in the table written
the tendency toward which answer.
The guideline included five ‘recommendations’ (R14,
R26, R31, R34, and R36) that did not have a described
condition or action, the so-called nonrecommendations.
These nonrecommendations were statements or observa-
tions that could not be appraised with the eGLIA instru-
ment. Therefore, we excluded them from further analyses.
When we analysed the global dimension, we found
three barriers to implementation (Q3-Q5). First, the
guideline did not address strategies for implementation
(Q3), although it seemed that dissemination of the
guideline had been undertaken with an online version.
Second, there was no tool for application (Q4) available,
such as a summary document. The electronic version
on the ESHRE website http://www.guidelines.endome-
triosis.org/ provided access to a concise summary and
supporting documentation, but the paper version of the
guideline did not refer to this. Third, the differences in
the importance of the recommendations (Q5) were only
described at the level of evidence. A clear presentation
or formatting reflecting the differences was lacking.
Regarding the individual recommendations, two were
straightforward to implement (R1 and R12). The remain-
ing 29 recommendations contained one or more barriers.
van Dijk et al. Implementation Science 2011, 6:7
http://www.implementationscience.com/content/6/1/7
Page 3 of 8Facilitators
The guideline scored very well on four dimensions,
which can be considered implementation facilitators.
First, the dimension of decidability (Q8-Q10) had posi-
tive scores for almost all recommendations. The descrip-
tion of the conditions and their mutual relations were
very clear. All recommendations were easily identifiable
because they were summarised in frames. Only two
recommendations (R19 and R32) had a vague definition
of the stated condition. For instance, the phrase
‘depending on the severity of the disease’ would need
further specification (R19).
Second, the recommendations were as concise as pos-
sible and their presentation and formatting (Q15 and
Q16) provided good visibility.
Third, the apparent validity (Q19 and Q20) was scored
as a facilitator due to the structured reporting of the
evidence and its quality linked to the individual
recommendations.
Fourth, in the dimension of novelty/innovation (Q21-
Q23), almost all recommendations were feasible without
the need of new skills or knowledge (Q21). Moreover,
the guideline considered the existing attitudes and
beliefs of the intended users of the guideline (Q22 and
Q23). However, R35 appeared incompatible with exist-
ing attitudes and beliefs of the guideline’si n t e n d e d
users because it favoured complementary medicine.
Barriers
Four barriers to implementation were identified. First,
the appraisers found that executability (Q11 and Q12)
was a barrier in various recommendations (R7, R9, R10,
R13, R15, and R33) because they were vague in their
descriptions of the recommended actions. Formulations
such as ‘consideration should be given’ did not make
clear whether the action should be carried out or not.
In addition, information about how a certain action
should be performed was missing. Measuring adherence
to such recommendations is difficult.
Second, the effect on the process of care (Q13 and
Q14) was identified as a barrier. Four recommendations
(R9, R11, R21, and R30) included actions that needed
extra equipment, staff, or provider time to make them
implementable. For example, not all hospitals have mag-
netic resonance imaging or facilities for in vitro fertilisa-
tion available.
Third, the lack of clear measures (Q17 and Q18) was
a barrier in seven recommendations (R5, R8, R10, R19,
R23, R24, and R35). There were no criteria for measur-
ing adherence to these recommendations, which could
complicate the monitoring of endometriosis care.
Fourth, the flexibility (Q24-Q27) was found to be a
barrier. Some recommendations (R7, R8, R10, R11, R15-
R17, R19, R33, and R35) lacked specific patient or
practice characteristics to enable individualisation of
care (Q24). Most recommendations (R2-R10, R13, R15-
R25, R27-R30, R32, R33, and R35) did not consider
coincident drug therapy and common comorbid condi-
tions (Q25). Furthermore, the incorporation of patient
preference (Q27) formed a barrier. R33 and R35 consid-
ered this preference but did not propose any mechan-
isms to implement the preference in practice. An
exception to flexibility as a barrier was the strength of
the recommendations (Q26), which the guideline devel-
opers stated explicitly with the classification of the
recommendations.
We excluded the four optional items from the dimen-
sion computability (Q28-Q31) from further analysis
because no electronic implementation was planned. At
the time of our study, information technology support
systems were not available to implement the guideline.
Of the 36 recommendations, 15 were graded with evi-
dence strength A. These recommendations (R6-R8, R16-
R18, R20, R22, R24, R25, R27-R29, R31, and R33) had
significantly fewer individual barriers for implementation
than the remaining recommendations did (Table 1).
Recommendations graded A had 26 barriers in 260
Table 1 Barriers related to the grade strength of the
evidence
Grading Items Barriers Proportion of barriers
to items
(in percentage)
Total
(in percentage)
A 260 26 10.0 26/260
(10.0)
B
C
D
GPP
19
51
19
226
3
5
4
40
15.8
9.8
21.1
17.7
52/315
(16.5)
Strength of evidence
Grade A: Directly based on level 1 evidence
Grade B: Directly based on level 2 evidence or extrapolated recommendation
from level 1 evidence
Grade C: Directly based on level 3 evidence or extrapolated recommendation
from either level 1 or level 2 evidence
Grade D: Directly based on level 4 evidence or extrapolated recommendation
from either level 1, 2, or 3 evidence
Grade GPP: Good practice point based upon the views of the Guideline
Development Group
Hierarchy of evidence
Level Evidence
1a Systematic review and meta-analysis of randomised controlled trials
1b At least one randomised controlled trial
2a At least one well-designed controlled study without randomisation
2b At least one other type of well-designed quasi-experimental study
3 Well-designed, nonexperimental, descriptive studies, such as comparative
studies, correlation studies, or case studies
4 Expert committee reports or opinions and/or clinical experience of
respected authorities
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levels B, C, D and the good practice points (p =. 0 2 ;
odds ratio = 0.5 [95% confidence interval, 0.3-0.9]).
General implementability of the guideline
The median score for the additional question assessing the
implementability of the guideline was 4, ranging from 2
(probably not implementable) to 5 (definitely implementa-
ble). Six appraisers (60%) thought that the guideline was
probably implementable (with some adjustments) or defi-
nitely implementable. One participant considered the
guideline as probably not implementable.
Process evaluation of eGLIA
On average, the time the participants spent completing
the appraisal (response 8 of 10) was four hours (range:
three to eight hours). The average time needed to com-
plete one recommendation was 10 minutes (range: 5 to
24 minutes). The answering became easier and quicker
as more recommendations were appraised.
Most participants (60%) found the explanation of the
GLIA dimensions and the use of the eGLIA tool clear
(Table 2). However, they commented that more scoring
examples would have been helpful. The general opinion
was that the eGLIA tool was easy to use (70%) and
functional for its purpose. Most questions were
appraised with an agreement of more than 60% (for the
answers ‘agree’ or ‘strongly agree’). Identifying obstacles
to implementation and judging the recommendations
systematically were consistently appraised with close
agreement (80% and 90%, respectively). There was wide
variation in the understanding and application of the
tool questions. Appraisers reported that several ques-
tions in the eGLIA instrument were not very clear or
that they had to read them several times to understand
the meaning. In addition, the participants stated that
appraising a large number of questions was boring and
too time consuming.
Discussion
The aim of this study was to investigate the implement-
ability of the ESHRE guideline for the diagnosis and
treatment of endometriosis with the aid of the eGLIA
tool. In general, the appraisers considered the guideline
implementable in daily practice. However, they identi-
fied important barriers to implementation for some
recommendations. This shows that barriers to imple-
mentation exist even in guidelines that are rated as
high-quality guidelines. Nonetheless, implementability
must be differentiated from guideline quality. Quality is
g e n e r a l l ya s s e s s e df o rt h eg u i d e l i n ea saw h o l ea n d
determines the scientific validity of guidelines. Imple-
mentability is one component of guideline quality, and
its assessment is applied to individual recommendations
within a guideline.
Implementation of the guideline would be improved if
a description of the implementation strategies was
included. The addition of an application tool for physi-
cians as well as for patients, e.g., a summary document
and a ‘coping with endometriosis’ leaflet, would also
likely enhance implementation. Furthermore, we advise
clearly displaying the most important recommendations
as key recommendations at the end of the guideline.
Appraisal of the implementability of individual recom-
mendations revealed important barriers that could be use-
ful in designing implementation strategies and in updating
the guideline. Recommendations could be reformulated to
optimise their use in daily practice. Using a standard for-
mat or template for formulating recommendations could
improve their implementability. The ESHRE has produced
a manual on guideline development http://www.eshre.eu/
ESHRE/English/Specialty-Groups/SIG/Safety-Quality-in-
ART/Manual-for-ESHRE-Guideline-Development/page.
aspx/254 comparable to the manuals of the National Insti-
tute for Health and Clinical Excellence [36] and the Amer-
ican Heart Association [37]. The manual states that
recommendations should be stand-alone texts (i.e., inde-
pendent from headings), and they should be as concise
but as detailed as possible. Each recommendation should
be a description about who does what for whom, when,
and how. Standard phrases are suggested to overcome
misunderstandings and confusion. A guiding structure of
developing guidelines and writing recommendations will
help prevent vaguely formulated recommendations and
‘nonrecommendations’. Ideally, a nonrecommendation
should be restated as a recommendation with conditions
and actions if possible. If this is not possible, the informa-
tion in the statement of the nonrecommendation can be
added in the supporting text. This way, the information is
retained but not listed as a recommendation. Furthermore,
conditions and actions should be defined concretely so
that only one interpretation is possible. For example, in
Table 2 Process evaluation of eGLIA
Questions (n = 10) Answers
DNA
The explanation of the GLIA dimensions is clear 2 2 6
The explanation of the use of the eGLIA tool is clear 0 1 9
The eGLIA tool is easy to use 2 1 7
The tool questions are easy to understand and apply 2 6 2
The tool questions were relevant to assessing
implementability
046
The eGLIA tool helped identify obstacles to implementation 1 1 8
The eGLIA helped to judge recommendations systematically 0 1 9
Will use the eGLIA more often 1 3 6
eGLIA = electronic guideline implementability appraisal; D = disagree or
strongly disagree; N = neutral; A = agree or strongly agree.
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of treatment could be classified as ‘prolonged’. As seen
from the results, grade A recommendations have fewer
barriers than those with a lower grade. This is most likely
because a grade A recommendation has a clearer evidence
base and can therefore be written unambiguously. A
recommendation should include clearly defined, measur-
able outcomes. For example, in R24, ‘the effectiveness of
hormonal treatment’ could be stated more explicitly, e.g.,
‘its effectiveness on achieving pregnancy’ or ‘its effective-
ness on giving birth’.
The implementability of a guideline should be consid-
ered in all phases of its development, including the
scoping phase; the evidence review; and the dissemina-
tion, adoption, and use of the guideline in practice
[15,38]. Applying guidelines requires good preparation,
with a detailed analysis of the target group, patient
involvement, systematic approach, and structured phras-
ing of the recommendations [7,12,39].
Process evaluation of eGLIA
The second aim of this study was to evaluate the useful-
ness and feasibility of the eGLIA instrument. The results
of this study indicate that the tool is useful in identify-
ing barriers to implementation and in appraising the
individual recommendations systematically. This is in
line with Hill and coworkers’ study [40]. Moreover, the
web-based eGLIA appraisal facilitates international col-
laboration and the availability of international guidelines.
The appraisers were widely distributed geographically.
However, the eGLIA tool made it easy to collect and
analyse the scores and to create a final report. This
report is helpful for the adjustment of certain recom-
mendations in a guideline to improve their implement-
ability without the need for developing a new guideline.
This obviates duplication ofe f f o r t[ 4 1 ] .T h ee G L I A
instrument is a tool that should be applied to each indi-
vidual recommendation. It gives good insight into
the barriers for implementation per recommendation.
The eGLIA instrument is not intended for assessment
of the implementability of the whole guideline, how-
ever, such an assessment would be an interesting
addition. A ranking of the implementability of the
individual recommendations could be considered, but
this alone would not be accurate because some recom-
mendations are substantially more important than
others.
A limitation of the eGLIA tool is the time necessary
for assessment. The eGLIA tool is probably unsuitable
for guidelines with many recommendations. This leads
to the question of practical use, in other words, the
implementability of the eGLIA instrument itself for
guidelines with many recommendations. To reduce the
appraisal time, we suggest the development of a concise
version of the current eGLIA instrument. For example,
some of the tool’s specific questions could be stated as
general questions in the global dimension of the guide-
line as a whole (Q15, Q16, Q19, Q20, and Q23) because
these questions -about format, validity, and patient
expectations- often have equal scores for all recommen-
dations. Other questions could be removed, as they have
limited additional value. For example, Q27 is about
patient preference, which is always considered and need
not be asked generally. Another possibility is short ques-
tions with marking of keywords, which would reduce
the reading time. Providing examples of ‘good’ recom-
mendations and ‘bad’ recommendations would facilitate
the scoring process.
Limitations of the study
First, most participants did not have any experience with
the eGLIA instrument. Therefore, they needed time to
understand the items and to learn about assessing the
recommendations. This is evident in the results: answer-
ing became easier and quicker as more recommenda-
tions were appraised. One participant (CM) had more
experience with the eGLIA instrument. She could give
directions and explain common problems in interpreting
the questions. A training workshop might be helpful
before starting a formal appraisal with the eGLIA
instrument.
Second, the process evaluation of the eGLIA instru-
ment was limited by the number of users (10) and the
number of guidelines (one). Formal validation would
need a larger group of appraisers and more guidelines in
different health areas. For international validation, trans-
lations of the instrument and translation protocols
should be developed. However, the study questionnaire
has revealed an interesting view of the use and feasibility
of the appraisal instrument.
Third, we investigated primarily factors intrinsic to the
guideline. We did not consider external factors, such as
organisational factors and environmental factors (e.g.,
lack of time and lack of resources). A supplementary
study could investigate these factors, possibly with a
focus group or individual interviews of patients and
professionals.
Fourth, both the appraisal of the guideline and the
evaluation of the eGLIA tool were involved. Negative
criticism of the eGLIA instrument may have interfered
with the reliability of the guideline evaluation. However,
the appraisers found the eGLIA tool useful and feasible
for its purpose. We therefore consider the appraisal of
the guideline valid.
The guideline developers and the eGLIA developers
received feedback. The ESHRE guideline for the diagno-
sis and treatment of endometriosis will be revised in
light of the results of this study.
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The ESHRE guideline for the diagnosis and treatment of
endometriosis has some intrinsic barriers to implemen-
tation, which could be overcome by more accurate and
systematic phrasing of the recommendations. For the
future development of ESHRE guidelines and other
guidelines, we recommend taking implementability
issues into account at the time of the drafting of the
guideline. The eGLIA tool might be useful and feasible
for this purpose. However, we also advise development
of a concise version of the eGLIA instrument.
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